234082-35-0

Basic information

• Product Name: 3-Chloro-4-fluoro Methyl benzoate
• Synonyms: 3-Chloro-4-fluoro Methyl benzoate;Chloro-4-fluorobenzoate;methyl 3-Chloro-6-fluorobenzoate
• CAS NO: 234082-35-0
• Molecular Formula: C₈H₆ClFO₂
• Molecular Weight: 189
• Mol File: 234082-35-0.mol

Chemical Properties

• Boiling Point: 238℃
• Flash Point: 102℃
• Appearance: /
• Density: 1.314
• Vapor Pressure: 0.0434mmHg at 25°C
• Refractive Index: 1.51
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-Chloro-4-fluoro Methyl benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-4-fluoro Methyl benzoate(234082-35-0)
• EPA Substance Registry System: 3-Chloro-4-fluoro Methyl benzoate(234082-35-0)

Safety Data

• Hazardous Substances Data: 234082-35-0(Hazardous Substances Data)

Usage

Chemical Properties

off-white powder

InChI:InChI=1/C8H6ClFO2/c1-12-8(11)5-2-3-7(10)6(9)4-5/h2-4H,1H3

Upstream product

• 67-56-1 methanol 
• 65055-17-6 3-chloro-4-fluorobenzoyl chloride 
• 403-16-7 3-chloro-4-fluorobenzoic acid 

Downstream Products

• 234082-16-7 methyl 3-chloro-4-(piperazin-1-yl)benzoate 
• 247035-32-1 methyl 3-chloro-4-(4-hydroxypiperidin-1-yl)benzoate 
• 879009-95-7 methyl 4-{(3S)-aminopiperidin-1-yl}-3-chlorobenzoate 
• 247035-35-4 methyl (4-aminopiperidin-1-yl)-3-chlorobenzoate 
• 247035-34-3 4-(4-azido-piperidin-1-yl)-3-chloro-benzoic acid methyl ester 
• 247035-33-2 methyl 3-chloro-4-{4-(methanesulfonyl-oxy)piperidin-1-yl}benzoate 
• 247035-36-5 methyl 3-chloro-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate 
• 247035-37-6 3-chloro-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoic acid 
• 247034-30-6 tert-butyl (2S)-benzenesulfonylamino-3-[3-chloro-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate 
• 234082-18-9 3-chloro-4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoic acid 
• 234082-17-8 methyl 3-chloro-4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoate 
• 234081-31-3 tert-butyl (2S)-benzenesulfonylamino-3-[3-chloro-4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoylamino]propionate 
• 863454-72-2 methyl 3-chloro-4-({3-[(1-methylethyl)oxy]-5-[(1,3-thiazol-2-ylamino)carbonyl]phenyl}oxy)benzoate 
• 863504-95-4 methyl 3-chloro-4-(3-[(1S)-2-methoxy-1-methylethyloxy]-5-{[(1-methyl-1H-pyrazol-3-yl)amino]carbonyl}phenoxy)benzoate 

Relevant articles and documents

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF

[Object] Provided is a compound which has an excellent S1P1 agonist action, and is useful particularly as an active ingredient for an agent for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease ind

Antileishmanial activity screening of 5-nitro-2-heterocyclic benzylidene hydrazides

A series of 53 nitro derivatives rationally designed were obtained by parallel synthesis and screened against Leishmania donovani. Six compounds exhibited IC50 values lower than standard drugs. Brief SAR analysis revealed that substitution is important to the activity. Nitrothiophene analogues were more potent than the nitrofuran ones. This was attributed to the ability of sulfur atoms in accommodating electrons from nitro group, which facilitate its reduction and therefore the formation of free radicals lethal to parasites.

PYRIDYL AND PHENYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

PROCESS FOR THE MANUFACTURE OF 4-FLUORO-ANTHRANILIC ACID

The present invention concerns a process for preparing 4-fluoro-anthranilic acid by nitration, reduction and hydrolysis of an alkyl 3-chloro-4-fluorobenzoate.